Brian Park, PharmD

Drug Information Specialist https://www.renalandurologynews.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Cardiovascular Disease (CVD)

Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial

Brian Park, PharmD

September 10, 2019

The Medicines Company announced topline results from the pivotal phase 3 ORION-11 study that evaluated the efficacy and safety of inclisiran, an investigational twice-yearly cholesterol-lowering therapy. Inclisiran is a chemically synthesized small interfering RNA (siRNA) that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA. The subcutaneous (SC) injectable is being investigated for its ability…

Prostate Cancer

FDA: Entacapone Not Associated With Increased Prostate Cancer Risk

Brian Park, PharmD

September 4, 2019

The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.

Next post in Prostate Cancer

Brian Park, PharmD

All articles by Brian Park, PharmD

Twice-Yearly Cholesterol-Lowering Therapy Effective in Phase 3 Trial

FDA: Entacapone Not Associated With Increased Prostate Cancer Risk

Re-Treatment With Radium-223 Appears Safe